ADVFN UK Market News

Category: Top Story

  • European Stocks Drift Lower as Earnings, Iran Tensions and Rate Outlook Weigh: DAX, CAC, FTSE100

    European Stocks Drift Lower as Earnings, Iran Tensions and Rate Outlook Weigh: DAX, CAC, FTSE100

    European equities traded slightly weaker in early dealings on Wednesday, with investors balancing a heavy flow of corporate results against geopolitical risks in the Middle East and upcoming central bank policy decisions.

    As of 07:34 GMT, the pan-European Stoxx 600 was down 0.1%. Germany’s DAX edged up 0.1%, while France’s CAC 40 slipped 0.2%. In London, the FTSE 100 declined 0.4%.

    Markets remain cautious as oil prices climb amid the ongoing conflict involving Iran, raising concerns about the broader impact on inflation, corporate earnings, and the trajectory of interest rates.

    Efforts to resolve tensions between the U.S. and Iran continue to stall, with little indication of progress. According to reports, Donald Trump has instructed aides to prepare for a prolonged blockade of Iranian ports, as policymakers face limited options to quickly de-escalate the situation.

    At the same time, the Strait of Hormuz remains largely inaccessible to tanker traffic. Given that the route typically handles about one-fifth of global oil flows, crude prices have remained elevated, fuelling fears of a wider energy shock.

    Earnings Parade

    Against this uncertain backdrop, a number of major European companies released quarterly updates.

    Adidas AG (BIT:1ADS) shares jumped more than 7% in early trading after the group delivered first-quarter operating profit ahead of expectations, despite what it described as a “very volatile and heavily discounted” retail environment.

    UBS Group AG (NYSE:UBS) also moved higher, supported by an 80% surge in first-quarter profit driven by strong trading and client activity amid heightened market volatility.

    STMicroelectronics (BIT:STMMI) advanced to its highest level since 2024 after reporting quarterly results that exceeded forecasts.

    Airbus SE (EU:AIR) edged up after reaffirming its full-year delivery targets, even as it continues to manage engine supply issues from Pratt & Whitney.

    Mercedes-Benz Group AG (TG:MBG) saw modest gains despite reporting lower revenue, largely due to increased competition from Chinese manufacturers.

    Banco Santander (LSE:BNC) traded near unchanged levels after posting a 12.5% rise in underlying net profit for the first quarter.

    GSK plc (LSE:GSK) fell more than 3%, even though it reaffirmed its 2026 outlook for revenue growth and expansion in core operating profit.

    Aena S.M.E. (BIT:1AENA) also declined following the release of its quarterly results.

    Looking ahead, attention is turning to the upcoming interest rate decision from the Federal Reserve later in the day. Policymakers are widely expected to leave rates unchanged, with market focus likely to shift toward guidance on the future path of borrowing costs.

  • FTSE 100 Falls as Iran Blockade Concerns Outweigh Strong Earnings

    FTSE 100 Falls as Iran Blockade Concerns Outweigh Strong Earnings

    The FTSE 100 moved lower on Wednesday as escalating geopolitical tensions overshadowed a series of positive corporate updates. Reports that Donald Trump is considering a prolonged economic blockade of Iran unsettled investors, signalling a shift toward sustained pressure rather than immediate military escalation.

    By 07:58 GMT, the FTSE 100 had declined 0.6%, while the pound weakened against the dollar to 1.3505. European markets also edged lower, with the DAX down 0.2% and the CAC 40 falling 0.4%.

    Market sentiment has been further impacted by stalled negotiations between the U.S. and Iran over Tehran’s nuclear programme, following a fragile ceasefire that has yet to evolve into a broader agreement. A key concern remains the continued disruption in the Strait of Hormuz, a critical passage for global energy supplies that typically handles around 20% of the world’s oil shipments. Iran has indicated it may maintain restrictions on the route in response to U.S. actions, heightening fears of prolonged supply constraints.

    Additional uncertainty has emerged after the United Arab Emirates signalled its exit from OPEC, potentially weakening coordination among oil producers and raising the risk of unaligned production decisions once shipping normalises. Together, these developments have kept oil prices elevated and increased concerns around inflation, tighter financial conditions, and slower global economic growth.

    UK Roundup

    Lloyds Banking Group plc (LSE:LLOY) reported first-quarter pre-tax profit of £2 billion, exceeding expectations on the back of stronger lending income. The bank also flagged risks linked to the Iran situation, taking a £151 million charge while maintaining its 2026 profit outlook.

    Aston Martin Lagonda Global Holdings plc (LSE:ASL) posted a narrower first-quarter operating loss of £56.9 million and secured £50 million in new funding from its core investor group. It reaffirmed full-year guidance but warned that instability in the Middle East could affect regional demand.

    Haleon plc (LSE:HLN) reported organic revenue growth of 2.2%, slightly missing expectations due to weaker international performance. The company maintained its full-year guidance, anticipating stronger contributions from North America.

    Jet2 plc (LSE:JET2) said summer bookings are up 7.7% year on year, reflecting resilient demand for travel. However, it noted that geopolitical uncertainty linked to Iran could affect peak-season occupancy, although fuel costs remain largely hedged.

    AstraZeneca plc (LSE:AZN) exceeded expectations in the first quarter, reporting earnings per share of $2.58 and an 8% increase in revenue to $15.29 billion, driven by strong demand for cancer treatments. The company maintained its full-year outlook.

    GSK plc (LSE:GSK) also delivered better-than-expected first-quarter results, supported by strong sales in respiratory and general medicines, outperforming analyst forecasts on both revenue and profit.

  • Lloyds Banking Group Reports Strong Q1 and Reaffirms 2026 Outlook

    Lloyds Banking Group Reports Strong Q1 and Reaffirms 2026 Outlook

    Lloyds Banking Group plc (LSE:LLOY) delivered a strong performance in the first quarter of 2026, reporting a 33% increase in statutory pre-tax profit to £2.0 billion. The growth was driven by higher net interest income, improved margins, and continued expansion in fee-based services, while operating costs remained controlled and credit quality stayed stable.

    During the quarter, lending volumes rose modestly, with loans increasing by 1%, while customer deposits remained broadly unchanged. The group also maintained solid capital generation, supporting its ability to reaffirm full-year guidance. Management continues to expect higher net interest income, a cost-to-income ratio below 50%, a return on tangible equity above 16%, and strong capital build through 2026, highlighting the resilience of its UK-focused business model despite ongoing economic uncertainty.

    Overall, the outlook is supported by a positive earnings trajectory and a constructive capital return strategy. However, some underlying concerns remain, including higher leverage levels and negative free cash flow over the past two years. Market indicators are broadly supportive, with a positive trend in the share price, though overbought signals suggest some near-term risk. Valuation and dividend yield provide additional support, though they are not considered exceptional.

    More about Lloyds Banking Group

    Lloyds Banking Group plc is a leading UK-focused retail and commercial bank offering a wide range of services, including personal banking, mortgages, business lending, wealth management, and insurance. The group operates through a portfolio of well-established brands and focuses on supporting UK households and businesses through a strategy centred on balance sheet strength, cost efficiency, and disciplined risk management.

  • GSK Delivers Strong Q1 Performance and Advances R&D Pipeline

    GSK Delivers Strong Q1 Performance and Advances R&D Pipeline

    GSK plc (LSE:GSK) began 2026 with solid momentum, reporting first-quarter sales of £7.6 billion, up 5% at constant exchange rates. Growth was driven by a 14% increase in Specialty Medicines, with strong double-digit gains in HIV, respiratory, and oncology treatments. Vaccines recorded modest growth, while general medicines declined. Core operating profit rose 10% and core earnings per share increased 9%, supported by a more favorable product mix, disciplined cost management, and higher royalty income.

    The company generated £0.8 billion in free cash flow during the quarter, enabling continued share buybacks and a 17p dividend. Management reaffirmed its full-year 2026 guidance, targeting low- to mid-single-digit revenue growth alongside high-single-digit expansion in core profit and earnings.

    GSK also highlighted accelerating progress across its research and development pipeline. The quarter included new approvals for treatments in asthma, COPD, and multiple myeloma, as well as global regulatory filings for hepatitis B candidate bepirovirsen. The company reported breakthrough and PRIME designations for its liver disease therapy efimosfermin and outlined plans for several pivotal trial readouts and oncology studies throughout 2026. These efforts are complemented by targeted acquisitions in areas such as food allergy and pulmonary hypertension.

    In addition, GSK confirmed that its 2026 outlook incorporates a new agreement with the U.S. government, which trades lower prescription drug prices for relief from potential Section 232 tariffs on patented pharmaceuticals through early 2029. This arrangement reduces a key policy risk for its U.S. business and provides greater visibility for investors.

    Overall, the company’s outlook is supported by strong profitability, improving fundamentals, and continued pipeline progress. Valuation appears reasonable, with a modest dividend yield, though some caution remains due to technical indicators suggesting overbought conditions and ongoing considerations around balance sheet strength and earnings consistency.

    More about GlaxoSmithKline

    GSK plc is a global biopharmaceutical company focused on developing and commercialising specialty medicines, vaccines, and general pharmaceuticals. It holds strong positions in key therapeutic areas including respiratory, HIV, oncology, and vaccines such as shingles and meningitis. The company aims to drive growth through higher-margin specialty products while managing a more mature general medicines portfolio across major global markets.

  • AstraZeneca Reports Robust Q1 Growth and Advances High-Value Drug Pipeline

    AstraZeneca Reports Robust Q1 Growth and Advances High-Value Drug Pipeline

    AstraZeneca plc (LSE:AZN) delivered a strong start to 2026, posting first-quarter total revenue of $15.3 billion, an 8% increase at constant exchange rates. Growth was led by double-digit gains in oncology and rare diseases, helping drive a 12% rise in core operating profit and a 5% increase in core earnings per share. Management reiterated its full-year outlook, expecting mid-to-high single-digit revenue growth and low double-digit core EPS expansion, supported by a projected 21% core tax rate and improving margins.

    The quarter also featured significant progress in the company’s late-stage pipeline. Positive Phase III trial results were reported for tozorakimab in chronic obstructive pulmonary disease and efzimfotase alfa in hypophosphatasia. AstraZeneca also secured 14 regulatory approvals across major markets and submitted several new applications, highlighting continued momentum in bringing new therapies to market.

    Strategic partnerships further strengthened its long-term growth profile. These included a $1.2 billion upfront collaboration with CSPC Pharmaceutical Group focused on obesity and type 2 diabetes, as well as licensing agreements with Jacobio Pharmaceuticals and Pinetree Therapeutics. These initiatives reflect AstraZeneca’s push into next-generation oncology treatments and metabolic therapies, supporting its ambitions through to 2030.

    Overall, the company’s outlook is underpinned by strong operational performance and a positive earnings trajectory, reinforced by pipeline advancements and strategic deals. However, valuation remains relatively elevated, with a price-to-earnings ratio around 30, while free cash flow has shown some variability. Technical indicators also suggest the stock may be somewhat overextended despite maintaining a broader upward trend.

    More about AstraZeneca

    AstraZeneca plc is a global biopharmaceutical company focused on the development and commercialization of prescription medicines. Its core therapeutic areas include oncology, rare diseases, cardiovascular, renal and metabolic conditions, as well as respiratory and immunology. The company emphasizes innovation through both internal research and strategic collaborations, particularly in advanced areas such as antibody-drug conjugates and next-generation metabolic treatments.

  • Aston Martin Boosts Margins on Specials as Revenue Climbs but Losses Continue

    Aston Martin Boosts Margins on Specials as Revenue Climbs but Losses Continue

    Aston Martin Lagonda Global Holdings plc (LSE:AML) reported first-quarter 2026 results broadly in line with expectations, with wholesale volumes holding steady at 939 vehicles. Revenue rose 16% to £270.4 million, largely driven by increased deliveries of high-end “Specials,” including 102 Valhalla units. A more premium product mix, combined with ongoing transformation initiatives, helped lift gross margin to 34.7% and pushed adjusted EBITDA into positive territory. However, the company still recorded a loss of £63 million for the quarter, while net debt increased to £1.46 billion, partly due to higher non-cash financing costs.

    Management reaffirmed its full-year 2026 outlook despite ongoing macroeconomic and geopolitical uncertainty. The company highlighted solid retail demand, a stable core order book, and continued expansion of its model lineup, including new DB12 S and Vantage S variants. Liquidity was strengthened through a £50 million committed facility from members of the Yew Tree Consortium, along with proceeds from the sale of Formula 1 naming rights. These measures lifted pro forma liquidity to around £230 million, although free cash outflow remained significant at £117 million during the quarter.

    The broader outlook remains challenged by weak financial fundamentals, including ongoing losses, elevated leverage, and continued cash burn. Technical indicators also point to downside pressure, with the stock trading well below key moving averages and showing negative momentum. While management’s guidance outlines a clearer path to improvement through 2026, near-term risks tied to liquidity and execution remain notable. Valuation support is limited, given the lack of profitability and absence of a dividend.

    More about Aston Martin Lagonda Global Holdings plc

    Aston Martin Lagonda Global Holdings plc is a British producer of luxury vehicles, specialising in high-performance sports cars, grand tourers, and SUVs. The brand operates in the premium and ultra-luxury segments, with a portfolio that includes limited-production Specials such as the Valhalla. Aston Martin sells its vehicles globally, with key markets spanning the Americas, Europe, the Middle East, and Asia-Pacific.

  • Prudential Posts Strong Q1 Growth and Announces Large Share Buyback

    Prudential Posts Strong Q1 Growth and Announces Large Share Buyback

    Prudential plc (LSE:PRU) delivered another quarter of solid expansion, reporting a 10% rise in new business profit to $686 million for Q1 2026. Annual premium equivalent (APE) sales also increased 6% to $1.82 billion on a constant currency basis. Profitability improved, with margins climbing two percentage points to 38%, supported by disciplined pricing strategies, a stronger mix of health and protection products, and continued emphasis on quality growth.

    Performance gains were seen across multiple regions and business lines. Markets such as Hong Kong, Mainland China, and Malaysia contributed strongly, while other Asian regions also supported overall growth. However, shifts in product mix in certain markets, including Singapore, limited the pace of margin expansion. The company pointed to the strength of its diversified distribution network—spanning agency and bancassurance channels—alongside ongoing advancements in agency transformation and digital capabilities. Meanwhile, its asset management arm maintained steady net inflows despite market-driven declines in funds under management. Prudential also announced a $1.2 billion share buyback for 2026, reinforcing its commitment to returning capital to shareholders despite ongoing geopolitical and inflationary pressures in parts of ASEAN.

    The overall assessment reflects a balance of strengths and challenges. Financial quality is improving, with better leverage metrics and a recovery in profitability. However, volatility remains a concern, particularly in earnings, revenue streams, and cash flow, highlighted by a notable drop in free cash flow during 2025. Management guidance and shareholder return initiatives provide a more positive outlook, though technical indicators remain weak, with the stock showing bearish momentum and trading below key moving averages. Valuation appears attractive, supported by a relatively low price-to-earnings ratio and a modest dividend yield.

    More about Prudential

    Prudential plc is an international life and health insurer and asset manager with a strategic focus on high-growth regions including Greater China, ASEAN, India, and Africa. The company offers a wide range of savings, protection, and investment products through a multi-channel distribution model. It maintains dual primary listings in Hong Kong and London, along with secondary listings in Singapore and New York via ADRs, and is a constituent of major market indices in Hong Kong and mainland China.

  • European stocks decline as investors await Big Tech earnings and Fed decision: DAX, CAC, FTSE100

    European stocks decline as investors await Big Tech earnings and Fed decision: DAX, CAC, FTSE100

    European equities moved lower on Tuesday, with investors adopting a cautious stance ahead of major technology earnings and the upcoming Federal Reserve policy decision.

    Geopolitical tensions also weighed on sentiment, as reports suggested the Trump administration is unlikely to accept Iran’s proposal to reopen the Strait of Hormuz while postponing discussions around its nuclear program.

    Iran’s defense ministry spokesperson Reza Talaei-Nik said the United States is no longer able to “dictate” its policies to sovereign nations and that Washington should “accept that it must abandon its illegal and irrational demands.”

    In the markets, Germany’s DAX Index fell 0.7%, France’s CAC 40 dropped 0.6%, and the U.K.’s FTSE 100 slipped 0.2%.

    Among individual stocks, Barclays (LSE:BARC) declined sharply after setting aside more than £800 million to cover potential losses linked to the collapse of a mortgage lender.

    Sweden’s Securitas (TG:S7MB) also came under pressure after reporting first-quarter earnings below expectations, impacted by currency headwinds.

    Novartis (NYSE:NVS) moved lower as the Swiss pharmaceutical group missed both sales and profit forecasts for the quarter.

    Air Liquide (EU:AI) also posted notable losses after reporting weaker-than-expected first-quarter revenue.

    Taylor Wimpey (LSE:TW.) dropped significantly after the U.K. homebuilder warned of ongoing pricing pressure and increased its expectations for build-cost inflation in 2026, citing higher energy costs.

    In contrast, Norwegian Air Shuttle (TG:NWC) surged after reporting a narrower net loss for the first quarter.

    Oil majors BP Plc (LSE:BP.) and Shell (LSE:SHEL) also gained, supported by rising crude prices, with Brent futures holding above $110 per barrel as efforts to resolve the U.S.-Iran conflict remain stalled.

  • European equities edge lower as Iran talks falter and oil prices rise: DAX, CAC, FTSE100

    European equities edge lower as Iran talks falter and oil prices rise: DAX, CAC, FTSE100

    European stock markets moved into negative territory at Tuesday’s open, as investors reacted to reports suggesting U.S. President Donald Trump may reject a proposal from Iran aimed at ending the two-month conflict.

    At 07:06 GMT, the pan-European Stoxx 600 was down 0.3%, while Germany’s DAX slipped 0.2%. France’s CAC 40 also declined 0.3%, and the UK’s FTSE 100 eased 0.1%.

    According to media reports, Trump is dissatisfied with Tehran’s latest offer, which would bring an end to hostilities and reopen the Strait of Hormuz but delay negotiations over Iran’s nuclear programme.

    The U.S. president has repeatedly emphasized that eliminating Iran’s nuclear capabilities—particularly any potential to develop nuclear weapons—has been a central objective of the joint U.S.-Israeli offensive launched in late February. As a result, Reuters reported, citing a U.S. official, that Trump views the proposal unfavorably.

    Optimism around renewed diplomatic efforts weakened over the weekend after Trump cancelled plans to send negotiators to Pakistan for another round of talks.

    Iran’s foreign minister made two brief visits to Islamabad before traveling to meet Russian President Vladimir Putin on Monday, where he reportedly secured support.

    Amid ongoing diplomatic tensions, the Strait of Hormuz remains largely closed to shipping. The strategic waterway, which handles roughly one-fifth of global oil supply, has been effectively shut for weeks, pushing crude prices significantly above pre-conflict levels.

    This situation has heightened concerns that rising energy costs could fuel global inflation, potentially prompting central banks to tighten monetary policy.

    Brent crude, the global oil benchmark, continued to climb on Tuesday.

    On the corporate front, shares of BP (LSE:BP.) rose after the UK energy major reported that first-quarter profit more than doubled year on year, supported by higher oil and gas prices.

    Norwegian Air Shuttle (USOTC:NWARF) also gained ground after posting a smaller-than-expected operating loss, helped in part by hedging strategies to offset rising jet fuel costs.

    Meanwhile, shares in Novartis (BIT:1NOVN) declined after the Swiss pharmaceutical company reported first-quarter core operating profit below market expectations.

  • FTSE 100 slips as Iran tensions and oil disruption weigh on sentiment

    FTSE 100 slips as Iran tensions and oil disruption weigh on sentiment

    UK equities edged lower at the open on Tuesday, as uncertainty surrounding U.S.-Iran negotiations and ongoing disruption to oil shipments through the Strait of Hormuz dampened investor confidence. Reports indicated that Donald Trump rejected Tehran’s proposal to reopen the crucial shipping route, adding to market unease.

    By 07:13 GMT, the FTSE 100 was down 0.10%, while sterling weakened against the dollar to 1.3506. Elsewhere in Europe, Germany’s DAX dropped 0.4% and France’s CAC 40 declined 0.3%.

    Markets remained cautious after reports suggested Washington was unconvinced by Iran’s proposal, particularly as it postpones discussions over the country’s nuclear programme.

    The U.S. has continued its naval blockade, leaving the Strait of Hormuz largely closed and restricting oil flows. As a result, crude prices stayed elevated, reflecting concerns over tighter supply and the breakdown of Pakistan-brokered talks over the weekend.

    Although an indefinite ceasefire remains in place, both sides appear reluctant to enter direct negotiations, increasing the risk of a prolonged diplomatic deadlock.

    UK Roundup

    BP (LSE:BP.) reported that a short-lived power outage at its refinery in Whiting, Indiana, forced the shutdown of one processing unit.

    Ineffable Intelligence secured $1.1 billion in seed funding led by major U.S. venture capital firms, with participation from the UK government.

    Chancellor Rachel Reeves is facing pressure from a House of Lords committee to commit to reducing public debt within three years.

    Retailers’ Easter promotions on items such as chocolate, home improvement products and clothing helped ease shop price inflation in April.

    A consumer advocacy group has launched a legal challenge against the £9.1 billion motor finance compensation scheme, drawing criticism from regulators.

    UK consumers’ inflation expectations declined in April, according to a YouGov survey conducted for Citigroup.